Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11633MR)

This product GTTS-WQ11633MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11633MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2598MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ3666MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ4166MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ1849MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ7302MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ7991MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ10961MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4203MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW